Literature DB >> 18261622

Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series.

Nora Sánchez-Mora1, Maria Cebollero Presmanes, Victor Monroy, Nicolas Moreno, Jose Manuel Lara-Martínez, Maria Herranz Aladro, Emilio Alvarez-Fernández.   

Abstract

The aims of the present work were to evaluate the prognostic significance of the micropapillary pattern of lung adenocarcinoma and determine whether there are differences in the behavior of this type of tumor according to its immunohistochemical profile. A series of 191 consecutively resected pulmonary adenocarcinomas were divided into those with (n = 62) and those without (n = 129) micropapillary components. The disease was stage I in 38 and 54 patients, respectively. The 5-year survival rates of patients with and without micropapillary components were 54% and 77%, respectively (log rank P = .03). In multivariate survival analysis, the micropapillary component proved to be an independent prognostic factor (hazard ratio, 3.2). Five autopsy cases were used to investigate the immunohistochemical profile. The percentages of cases positive for various markers were 56.7 for p53, 94 for Ki67, 85.1 for c-myc, 2.9 for Bcl-2, 35.8 for epidermal growth factor receptor, 43.3 for cyclin D1, and 46.3 for Bax. The prognostic value was evaluated according to the expression of the different markers in micropapillary carcinomas in stage I. In univariate analysis, only cyclin D1 expression and Bax expression were associated with significantly worse survival (log rank P = .03 and P = .02, respectively). We conclude that it is important to recognize the micropapillary growth pattern in lung adenocarcinoma. Moreover, cyclin D1 and Bax seem to be markers of a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18261622     DOI: 10.1016/j.humpath.2007.05.029

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  25 in total

1.  Esophageal adenosquamous carcinoma mimicking acantholytic squamous cell carcinoma.

Authors:  Susumu Matsukuma; Oh Takahashi; Yoshitaka Utsumi; Masaki Tsuda; Kosuke Miyai; Kenji Okada; Hiroaki Takeo
Journal:  Oncol Lett       Date:  2017-08-23       Impact factor: 2.967

2.  Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile.

Authors:  Carrie C Lubitz; Konstantinos P Economopoulos; Amanda C Pawlak; Kerry Lynch; Dora Dias-Santagata; William C Faquin; Peter M Sadow
Journal:  Thyroid       Date:  2014-03-06       Impact factor: 6.568

3.  The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know.

Authors:  Takashi Eguchi; Kyuichi Kadota; Bernard J Park; William D Travis; David R Jones; Prasad S Adusumilli
Journal:  Semin Thorac Cardiovasc Surg       Date:  2014-09-16

4.  Genetic alterations in lung adenocarcinoma with a micropapillary component.

Authors:  Masashi Furukawa; Shinichi Toyooka; Kouichi Ichimura; Hiromasa Yamamoto; Junichi Soh; Shinsuke Hashida; Mamoru Ouchida; Kazuhiko Shien; Hiroaki Asano; Kazunori Tsukuda; Shinichiro Miyoshi
Journal:  Mol Clin Oncol       Date:  2015-12-02

5.  Accuracy of the IASLC/ATS/ERS histological subtyping of stage I lung adenocarcinoma on intraoperative frozen sections.

Authors:  Humberto E Trejo Bittar; Pimpin Incharoen; Andrew D Althouse; Sanja Dacic
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

Review 6.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

7.  Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis.

Authors:  Maristela L Onozato; Alexandra E Kovach; Beow Y Yeap; Vicente Morales-Oyarvide; Veronica E Klepeis; Swathi Tammireddy; Rebecca S Heist; Eugene J Mark; Dora Dias-Santagata; A John Iafrate; Yukako Yagi; Mari Mino-Kenudson
Journal:  Am J Surg Pathol       Date:  2013-02       Impact factor: 6.394

8.  Lung adenocarcinomas with micropapillary components.

Authors:  Ryo Maeda; Noritaka Isowa; Hideyuki Onuma; Hiroshi Miura; Tomoya Harada; Hirokazu Touge; Hirokazu Tokuyasu; Yuji Kawasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-10-16

Review 9.  Histopathologic and molecular approach to staging of multiple lung nodules.

Authors:  Frank Schneider; Sanja Dacic
Journal:  Transl Lung Cancer Res       Date:  2017-10

10.  SUMOylation of RhoGDIα is required for its repression of cyclin D1 expression and anchorage-independent growth of cancer cells.

Authors:  Zipeng Cao; Xueyong Li; Jingxia Li; Beipei Kang; Jingyuan Chen; Wenjing Luo; Chuanshu Huang
Journal:  Mol Oncol       Date:  2013-12-03       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.